Skip to main content

Advertisement

SpringerLink
Log in

Acute myeloid leukemia

Biomarkers for RBM39 degradation in acute myeloid leukemia

  • Letter
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Indisulam activity and assay development for RBM39 degradation detection in patient AML.
Fig. 2: Indisulam induces splicing alterations in patient AML specimens and development of a RT-PCR assay for splicing alteration detection.

References

  1. Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004;10:4680–7.

    Article  CAS  Google Scholar 

  2. Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schoffski P, et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol. 2005;16:158–61.

    Article  CAS  Google Scholar 

  3. Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2007;13:1816–22.

    Article  CAS  Google Scholar 

  4. Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356:397.

  5. Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat Chem Biol. 2017;13:675–80.

    Article  CAS  Google Scholar 

  6. Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35:369–84.e367.

    Article  Google Scholar 

  7. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018;124:2758–65.

    Article  CAS  Google Scholar 

  8. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732–6.

    Article  CAS  Google Scholar 

  9. Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2016;44:D1018–22.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank members of the Nijhawan lab for helpful advice and discussions. DH was supported by a training award from the American Society of Hematology. DN is supported by Welch Foundation I-1879, NIH R37CA226771, and NIH RO1CA217333. This work was supported in part by funds from Peloton Therapeutics, now a wholly owned subsidiary of Merck, and a grant from the Simmons Cancer Center at UT Southwestern.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    David Hsiehchen, Maria Goralski & Deepak Nijhawan

  2. Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Jiwoong Kim & Yang Xie

  3. Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Yang Xie & Deepak Nijhawan

  4. Harold C. Simmons Comprehensive Cancer Center, University of Texas Medical Center, Dallas, TX, USA

    Deepak Nijhawan

Authors
  1. David Hsiehchen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Goralski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiwoong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deepak Nijhawan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DH participated in the design, executed all of the experiments, and wrote the paper. MG optimized the FACS based assay for RBM39 degradation. JK analyzed RNA sequencing and generated list of splicing alterations. YX is a supervisor for JK, DN conceived the study, designed the experiments, and wrote the paper.

Corresponding author

Correspondence to Deepak Nijhawan.

Ethics declarations

Conflict of interest

DN is a consultant for Peloton Therapeutics, now a wholly owned subsidiary of Merck. The other authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hsiehchen, D., Goralski, M., Kim, J. et al. Biomarkers for RBM39 degradation in acute myeloid leukemia. Leukemia 34, 1924–1928 (2020). https://doi.org/10.1038/s41375-020-0729-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0729-9

  • Springer Nature Limited

This article is cited by

Search

Navigation